Ser372

Site Information
DEsEsAAssRAPsPP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4727196

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:	293E (epithelial) ( 2 ) , 293GP (epithelial) [NPM-ALK (human), transfection] ( 4 ) , HeLa (cervical) ( 3 ) , WM239A (melanocyte) ( 1 )

Upstream Regulation
Treatments:	rapamycin ( 2 )

References
1	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
2	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
3	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
4	Wu F, et al. (2010) Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics 9, 1616-32 20393185 Curated Info